We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 09, 2021

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy for Non-Metastatic TNBC

Clinical Cancer Research


Additional Info

Clinical Cancer Research
A Phase 1 Trial of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy for the Treatment of Non-Metastatic Triple-Negative Breast Cancer
Clin. Cancer Res 2020 Dec 23;[EPub Ahead of Print], H Soliman, D Hogue, HS Han, B Mooney, R Lima Barros Costa, MC Lee, B Niell, A Williams, A Chau, S Falcon, N Khakpour, RJ Weinfurtner, S Hoover, J Kiluk, M Rosa, H Khong, BJ Czerniecki

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading